RARE News and Press, Ultragenyx Pharmaceutical Inc. From 01/08/24

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on de...

Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $325 million to $330 million and Dojolvi® revenue of $70 million to $71 million 2024 expected Total Revenue guidance between $500 million to $530 million, Crysvita revenue of $375 millio...

NOVATO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending Evkeeza® (evinacumab) to NHS England. Evkeeza is recommended within...

NOVATO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced the completion of patient enrollment in...

NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the c...

2023-12-24 09:48:14 ET Summary Ultragenyx Pharmaceuticals' shares are trading 60% higher after pricing a secondary offering, reflecting optimism about its pipeline of rare disease treatments. The company has four commercial products, with Crysvita generating the majority of its re...

2023-12-23 21:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-21 17:57:17 ET More on Ultragenyx Pharmaceutical Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade) Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. 2023 Q3 - Res...

NOVATO, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Commission (EC) has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years w...

2023-12-08 17:07:24 ET More on Ultragenyx Pharmaceutical Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade) Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript Ultragenyx Pharmaceutical Inc. 2023 Q3 - Res...